baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

HSBC Knock-Out REGN/ DE000TT7Q2T5 /

10/4/2024 9:36:11 PM	Chg.+0.02	Bid10:00:39 PM	Ask10:00:39 PM	Underlying	Strike price	Expiration date	Option type
3.43EUR	+0.59%	- Bid Size: -	- Ask Size: -	Regeneron Pharmaceut...	640.6955 USD	12/31/2078	Call

GlobeNewswire 8/28 Kiniksa Pharmaceuticals to Present at 2024 Wells Fargo Healthcare Conference

GlobeNewswire 8/26 Ordspono™ (odronextamab) Approved in the European Union for the Treatment of Relapsed/Refractory Fol...

GlobeNewswire 8/26 Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadersh...

GlobeNewswire 8/21 Regeneron Provides Update on Biologics License Application for Linvoseltamab

GlobeNewswire 8/15 Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of ...

GlobeNewswire 8/15 European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimi...

GlobeNewswire 8/12 Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar po...

GlobeNewswire 8/8 Intellia Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Recent Company ...

GlobeNewswire 8/7 Regeneron Announces Investor Conference Presentations and Oncology Investor Webcast

GlobeNewswire 8/5 BioNTech Announces Second Quarter 2024 Financial Results and Corporate Update

GlobeNewswire 8/1 Regeneron Reports Second Quarter 2024 Financial and Operating Results

GlobeNewswire 7/31 Regeneron Announces the 2024 Winners of the Regeneron Prize for Creative Innovation

GlobeNewswire 7/23 Kiniksa Pharmaceuticals Reports Second Quarter 2024 Financial Results and Recent Portfolio Execution

GlobeNewswire 7/23 BridgeBio Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer

GlobeNewswire 7/16 Kiniksa Pharmaceuticals to Report Second Quarter 2024 Financial Results on July 23, 2024

GlobeNewswire 7/10 Regeneron Pharmaceuticals, Inc. Investors: Company Investigated by the Portnoy Law Firm

GlobeNewswire 7/7 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharma...

GlobeNewswire 7/3 Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients...

GlobeNewswire 7/3 Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD

GlobeNewswire 6/30 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharma...

GlobeNewswire 6/28 Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphom...

GlobeNewswire 6/27 Regeneron to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and...

GlobeNewswire 6/26 Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esoph...

GlobeNewswire 6/26 Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic e...

GlobeNewswire 6/22 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharma...

HSBC Knock-Out REGN/ DE000TT7Q2T5 /

If you wish to receive reply to your feedback, please provide your email address.